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Continuous	  subcutaneous	  insulin	  infusion	  (CSII),	  or	  insulin	  pump	  therapy,	  is	  an	  important	  and	  
effective	  treatment	  option	  for	  patients	  with	  diabetes.	  	  To	  date,	  CSII	  is	  largely	  utilized	  in	  the	  type	  
1	  diabetic	  population.	  	  As	  demonstrated	  in	  the	  following	  case	  report,	  initiation	  of	  CSII	  for	  a	  type	  
1	  brittle	  diabetic	  was	  effective	  in	  gaining	  glycemic	  control.	  	  Of	  the	  29.1	  million	  people	  diagnosed	  
with	  diabetes,	  90-­‐95%	  have	  type	  2	  diabetes.	  	  As	  the	  patient	  with	  type	  2	  diabetes	  becomes	  more	  
insulin	  resistant,	  multiple	  daily	  injections	  (MDI)	  of	  insulin	  are	  needed	  to	  attain	  glycemic	  control,	  
but	  oftentimes	  these	  efforts	  fail.	  	  A	  literature	  review	  was	  performed	  to	  determine	  whether	  CSII	  
versus	  MDI	  in	  the	  uncontrolled	  type	  2	  diabetic	  patient	  would	  improve	  patient	  outcomes	  based	  
on	  the	  factors	  of	  effectiveness,	  safety,	  and	  cost-­‐efficiency.	  	  Evidence	  suggests	  that	  while	  CSII	  
therapy	  is	  effective	  at	  lowering	  hemoglobin	  A1c,	  and	  is	  safe	  in	  regards	  to	  both	  reducing	  
hypoglycemic	  events	  and	  in	  operating	  the	  insulin	  pump,	  it	  may	  not	  be	  cost	  efficient	  due	  to	  
limited	  insurance	  coverage	  for	  this	  population.	  	  Being	  that	  CSII	  effectively	  attains	  glycemic	  
goals,	  risks	  for	  complications	  from	  poor	  glycemic	  control	  are	  reduced.	  	  More	  research	  and	  cost	  
analysis	  is	  needed	  to	  determine	  if	  the	  expense	  of	  CSII	  outweighs	  the	  medical	  costs	  of	  











	   In	  the	  United	  States,	  diabetes	  mellitus	  affects	  an	  estimated	  29.1	  million	  people.	  	  It	  was	  
the	  7th	  leading	  cause	  of	  death	  in	  2010,	  and	  in	  2012,	  accrued	  $245	  billion	  in	  direct	  and	  indirect	  
medical	  costs	  (Centers	  for	  Disease	  Control	  and	  Prevention,	  2015).	  	  A	  diagnosis	  of	  diabetes	  can	  
be	  devastating.	  Alongside	  financial	  burdens,	  Healthy	  People	  2020	  discusses	  that	  diabetes	  also	  
“lowers	  life	  expectancy	  by	  up	  to	  15	  years,	  increases	  the	  risk	  of	  heart	  disease	  by	  two	  to	  four	  
times,	  and	  is	  the	  leading	  cause	  of	  kidney	  failure,	  lower	  limb	  amputations,	  and	  adult-­‐onset	  
blindness”	  (Office	  of	  Disease	  Prevention	  and	  Health	  Promotion,	  2014).	  	  Fortunately,	  there	  are	  
many	  tools	  available	  to	  manage	  diabetes	  and	  proper	  management	  can	  significantly	  reduce	  the	  
risks	  of	  complications	  from	  diabetes.	  This	  is	  illustrated	  in	  the	  following	  case.	  	  	  
	   A	  67-­‐year	  old	  male	  presents	  for	  a	  preoperative	  exam	  for	  a	  right	  total	  knee	  replacement.	  	  
His	  past	  medical	  history	  includes	  type	  1	  diabetes	  mellitus,	  hypertension,	  and	  hyperlipidemia.	  	  
He	  was	  diagnosed	  with	  type	  1	  diabetes	  in	  his	  early	  adulthood	  and	  has	  considered	  himself	  a	  
brittle	  diabetic	  for	  most	  of	  his	  life.	  	  Three	  years	  ago,	  he	  transitioned	  his	  diabetic	  management	  
from	  multiple	  daily	  injections	  of	  insulin	  (MDI)	  to	  continuous	  subcutaneous	  insulin	  infusion	  
(CSII),	  most	  commonly	  referred	  to	  as	  insulin	  pump	  therapy.	  	  After	  over	  40	  years	  of	  struggle	  in	  
managing	  his	  disease,	  this	  transition	  was	  what	  this	  patient	  needed	  to	  take	  adequate	  control	  of	  
his	  diabetes.	  	  
	   Research	  suggests	  that	  using	  insulin	  pump	  therapy	  assists	  patients	  affected	  by	  type	  1	  
diabetes	  to	  meet	  their	  goals	  and	  reduce	  long-­‐term	  complications.	  	  Due	  to	  its	  proven	  benefit,	  
Medicare,	  as	  well	  as	  private	  insurance	  carriers,	  help	  defer	  the	  cost	  of	  insulin	  pump	  therapy	  for	  
type	  1	  diabetes.	  	  Strikingly,	  of	  those	  diagnosed	  with	  diabetes,	  type	  1	  accounts	  for	  only	  5%,	  while	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type	  2	  encompasses	  90-­‐95%	  of	  total	  diagnosed	  cases	  (Centers	  for	  Disease	  Control	  and	  
Prevention,	  2015).	  	  While	  limited	  studies	  have	  been	  performed	  regarding	  insulin	  pump	  therapy	  
for	  the	  patient	  with	  type	  2	  diabetes,	  is	  there	  enough	  evidence	  to	  suggest	  that	  the	  patient	  with	  
uncontrolled	  type	  2	  diabetes	  would	  have	  improved	  outcomes	  with	  insulin	  pump	  therapy	  versus	  
multiple	  daily	  insulin	  injections?	  	  With	  this	  literature	  review,	  an	  attempt	  will	  be	  made	  to	  answer	  
this	  question	  as	  well	  as	  whether	  insulin	  pump	  therapy	  is	  safe,	  effective,	  and	  cost-­‐efficient	  for	  
this	  population.	  
Case	  Report	  	  
	   The	  patient	  who	  presented	  for	  his	  preoperative	  examination	  was	  considered	  a	  brittle	  
diabetic	  and	  had	  been	  diagnosed	  with	  type	  1	  diabetes	  in	  his	  early	  twenties.	  	  The	  National	  
Institute	  of	  Diabetes	  and	  Digestive	  and	  Kidney	  Diseases	  (2014)	  describes	  type	  1	  diabetes	  as	  
when	  “your	  body	  no	  longer	  makes	  insulin	  or	  enough	  insulin	  because	  the	  body’s	  immune	  system	  
has	  attacked	  and	  destroyed	  the	  pancreatic	  cells	  that	  make	  insulin”.	  	  Type	  2	  diabetes	  develops	  
differently,	  beginning	  with	  the	  body’s	  resistance	  to	  insulin	  and	  advancing	  to	  the	  point	  where	  
the	  pancreas	  is	  unable	  to	  make	  enough	  insulin	  to	  combat	  blood	  glucose	  levels.	  	  As	  type	  2	  
diabetes	  advances,	  the	  body	  starts	  to	  depend	  on	  insulin	  injections	  for	  blood	  glucose	  control	  
(National	  Institute	  of	  Diabetes	  and	  Digestive	  and	  Kidney	  Diseases,	  2014).	  	  Due	  to	  the	  disease,	  
this	  patient	  is	  dependent	  upon	  insulin	  injections	  and	  strict	  monitoring	  of	  dietary	  choices	  to	  
regulate	  his	  blood	  glucose.	  	  For	  40	  years	  of	  this	  patient’s	  life,	  he	  was	  giving	  himself	  shots	  of	  
insulin	  multiple	  times	  per	  day	  and	  he	  was	  still	  uncontrolled.	  	  Just	  three	  years	  ago,	  he	  was	  placed	  
on	  insulin	  pump	  therapy	  and	  has	  since	  attained	  glycemic	  control.	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   Glycemic	  control	  is	  determined	  by	  hemoglobin	  A1c	  monitoring,	  which	  correlates	  to	  an	  
average	  reading	  of	  blood	  glucose	  levels	  over	  a	  two-­‐	  to	  three-­‐month	  period.	  	  The	  American	  
Diabetes	  Association	  (2016)	  defines	  a	  normal	  hemoglobin	  A1c	  as	  <5.7%,	  pre-­‐diabetes	  as	  5.7%	  to	  
6.4%,	  and	  diabetes	  as	  any	  number	  greater	  than	  6.5%.	  	  After	  diagnosis	  of	  diabetes,	  the	  goal	  is	  to	  
reduce	  hemoglobin	  A1c	  to	  near-­‐normal	  levels,	  but	  health	  status	  and	  patient	  individualization	  is	  
taken	  into	  account.	  	  According	  to	  the	  guideline	  published	  by	  the	  National	  Guideline	  
Clearinghouse,	  Diagnosis	  and	  Management	  of	  Type	  2	  Diabetes	  Mellitus	  in	  Adults,	  hemoglobin	  
A1c	  should	  be	  individualized	  for	  each	  patient	  in	  a	  range	  from	  <7%	  to	  <8%	  (Agency	  for	  
Healthcare	  Research	  and	  Quality,	  2014).	  	  Achieving	  near	  normal	  levels,	  lowers	  the	  risk	  of	  
microvascular	  complications	  such	  as	  retinopathy,	  nephropathy,	  and	  amputations	  and	  may	  also	  
significantly	  reduce	  macrovascular	  complications	  such	  as	  heart	  attack	  and	  stroke	  (Agency	  for	  
Healthcare	  Research	  and	  Quality,	  2014).	  	  This	  patient	  has	  annual	  eye	  exams	  with	  no	  evidence	  of	  
retinopathy,	  his	  renal	  function	  is	  adequate	  based	  on	  his	  BUN	  of	  9mg/dL	  and	  creatinine	  of	  0.8	  
mg/dL.	  	  He	  has	  no	  evidence	  of	  peripheral	  neuropathy,	  peripheral	  vascular	  disease,	  and	  has	  not	  
had	  a	  heart	  attack	  or	  stroke.	  	  	  
This	  patient	  had	  his	  hemoglobin	  A1c	  checked	  as	  part	  of	  the	  preoperative	  examination	  
and	  his	  result	  was	  7.0%.	  	  Alongside	  hemoglobin	  A1c	  levels,	  a	  patient	  should	  also	  be	  monitoring	  
finger	  stick	  blood	  glucose	  readings	  at	  home.	  	  Multiple	  readings	  throughout	  the	  day	  will	  guide	  
the	  patient	  in	  dosing	  insulin	  injections	  and	  in	  preventing	  episodes	  of	  hypo-­‐	  or	  hyperglycemia.	  	  
When	  he	  checks	  his	  blood	  glucose	  at	  home,	  his	  numbers	  range	  from	  140-­‐180	  mg/dL.	  	  He	  also	  
reports	  that	  since	  starting	  pump	  therapy,	  his	  incidences	  of	  hyperglycemia	  have	  been	  rare.	  	  
Episodes	  of	  hypoglycemia	  have	  been	  more	  frequent,	  but	  only	  in	  the	  last	  six	  weeks	  since	  his	  left	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knee	  surgery	  and	  have	  been	  caught	  quickly	  and	  resolved.	  	  He	  attributes	  the	  low	  readings	  to	  
increased	  exercise	  and	  therapy	  after	  his	  left	  knee	  replacement	  and	  having	  less	  of	  an	  appetite	  
while	  taking	  pain	  medications.	  	  He	  had	  one	  very	  low	  blood	  glucose	  in	  the	  pre-­‐operative	  period	  
before	  his	  last	  surgery,	  which	  was	  resolved	  with	  a	  glucagon	  intramuscular	  injection.	  	  Despite	  
these	  findings,	  his	  lab	  results	  show	  that	  his	  blood	  glucose	  over	  time	  has	  been	  well-­‐managed,	  
which	  has	  decreased	  his	  risk	  for	  complications.	  	  
	   Diabetes	  predisposes	  an	  individual	  for	  microvascular	  and	  macrovascular	  complications	  
and	  comorbidities.	  	  Microvascular	  refers	  to	  the	  smaller	  blood	  vessels	  of	  the	  body	  and	  include	  
complications	  such	  as	  retinopathy,	  nephropathy,	  and	  peripheral	  vascular	  disease	  leading	  to	  
amputations.	  	  Diabetes	  also	  puts	  patients	  at	  risk	  for	  macrovascular	  disease	  such	  as	  
cardiovascular	  disease,	  so	  management	  of	  cardiovascular	  risks	  is	  very	  important.	  	  This	  same	  
patient	  has	  a	  history	  of	  hypertension,	  hyperlipidemia,	  and	  tobacco	  use.	  	  To	  manage	  these	  
diseases,	  he	  is	  taking	  Losartan	  10mg	  daily,	  Simvastatin	  80mg	  daily,	  and	  aspirin	  81mg	  daily.	  	  He	  
continues	  to	  smoke	  1	  pack	  per	  day,	  and	  smoking	  cessation	  efforts	  have	  been	  addressed.	  	  He	  has	  
annual	  visits	  with	  a	  cardiologist	  to	  monitor	  for	  heart	  disease,	  and	  he	  sees	  endocrinology	  and	  his	  
primary	  care	  physician	  where	  he	  has	  his	  blood	  work	  monitored	  on	  a	  regular	  basis.	  	  	  	  
	   This	  patient’s	  physical	  exam	  revealed	  grossly	  normal	  findings,	  except	  for	  an	  elevated	  
blood	  pressure	  of	  158/94,	  which	  came	  down	  towards	  the	  end	  of	  the	  exam.	  	  He	  also	  had	  some	  
swelling	  and	  limited	  range	  of	  motion	  of	  the	  left	  knee	  due	  to	  previous	  surgery.	  	  Because	  this	  
patient	  has	  been	  well-­‐managed,	  adhering	  to	  his	  medications,	  utilizing	  insulin	  pump	  therapy,	  
and	  following	  recommendations	  for	  diet	  and	  exercise,	  he	  was	  cleared	  for	  his	  upcoming	  surgery.	  	  
He	  was	  also	  advised	  to	  adhere	  to	  strict	  monitoring	  of	  finger	  stick	  blood	  glucose	  measurements	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in	  the	  perioperative	  and	  post-­‐operative	  phase	  due	  to	  a	  history	  of	  hypoglycemia	  prior	  to	  his	  last	  
surgery	  related	  to	  decreased	  oral	  intake	  and	  during	  recovery	  due	  to	  increased	  exercise.	  	  He	  will	  
follow	  up	  with	  the	  surgeon	  at	  two	  weeks	  and	  six	  weeks	  post-­‐operatively.	  	  He	  will	  also	  see	  his	  
endocrinologist	  every	  six	  months	  for	  diabetic	  management	  and	  his	  primary	  care	  provider	  every	  
year	  for	  a	  physical	  and	  chronic	  disease	  management.	  	  The	  patient	  was	  agreeable	  to	  this	  plan.	  	  
Literature	  Review	  
	   Insulin	  pump	  therapy	  is	  a	  viable	  option	  for	  the	  brittle,	  type	  1	  diabetic	  population.	  	  It	  has	  
been	  shown	  to	  be	  safe,	  improve	  patient	  outcomes,	  and	  be	  cost	  effective	  due	  to	  insurance	  
companies’	  willingness	  to	  cover	  all	  or	  part	  of	  this	  therapy	  (Misso,	  Egberts,	  Page,	  O’Connor,	  &	  
Shaw,	  2010).	  	  Intensive	  glucose	  control	  also	  reduces	  the	  overall	  risk	  of	  microvascular	  
complications	  and	  major	  macrovascular	  outcomes	  such	  as	  heart	  attack	  and	  stroke	  (Fullerton	  et	  
al.,	  2014).	  	  According	  to	  the	  Centers	  for	  Disease	  Control	  and	  Prevention	  (2016),	  in	  the	  United	  
States,	  29.1	  million	  people	  have	  diabetes	  which	  may	  also	  be	  considered	  as	  one	  out	  of	  eleven	  
people.	  	  Of	  those	  individuals,	  nine	  out	  of	  ten	  have	  type	  2	  diabetes.	  Being	  that	  type	  2	  diabetes	  
has	  become	  prevalent	  in	  our	  population,	  a	  literature	  review	  was	  performed	  in	  an	  attempt	  to	  
discover	  whether	  insulin	  pump	  therapy	  versus	  multiple	  daily	  injections	  of	  insulin	  in	  the	  patient	  
with	  uncontrolled	  type	  2	  diabetes	  improve	  patient	  outcomes	  in	  terms	  of	  effectiveness,	  safety,	  
and	  cost-­‐efficiency.	  	  
	   To	  answer	  a	  therapy-­‐related	  question	  such	  as	  this,	  the	  strongest	  evidence	  would	  come	  
from	  systematic	  reviews,	  randomized	  control	  trials	  (RCTs),	  or	  meta-­‐analyses	  of	  all	  the	  current	  
related	  RCTs.	  	  Using	  the	  University	  of	  North	  Dakota’s	  Harley	  E.	  French	  Library	  of	  Health	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Sciences,	  a	  variety	  of	  databases	  were	  accessed	  including	  Cochrane	  Library,	  Cumulative	  Index	  to	  
Nursing	  and	  Allied	  Health	  Literature	  (CINAHL),	  and	  PubMed.	  
First,	  a	  search	  was	  performed	  on	  the	  Cochrane	  Library	  Database	  in	  order	  to	  find	  
systematic	  reviews.	  Medical	  subject	  headings,	  or	  MeSH	  terms,	  “diabetes	  mellitus”	  and	  “insulin	  
pump	  therapy”	  revealed	  402	  articles	  to	  review;	  17	  of	  which	  were	  categorized	  as	  systematic	  
reviews,	  15	  other	  reviews,	  356	  trials,	  10	  technology	  assessments,	  and	  four	  economic	  
evaluations.	  	  Three	  reviews	  pertinent	  to	  the	  topic	  were	  kept	  for	  consideration,	  while	  limiting	  
the	  search	  further.	  	  Next	  “diabetes	  mellitus	  type	  2”	  and	  “insulin	  pump	  therapy”	  were	  keyed	  in	  
as	  MeSH	  terms.	  This	  search	  produced	  28	  results	  including	  six	  systematic	  reviews,	  two	  other	  
reviews,	  and	  20	  trials.	  	  The	  systematic	  reviews	  were	  duplicate	  matches	  of	  the	  search	  prior.	  	  Out	  
of	  this	  search,	  four	  trials	  were	  extracted	  for	  interpretation.	  	  
CINAHL	  was	  the	  next	  database	  to	  be	  accessed.	  	  MeSH	  terms	  “insulin	  pump	  therapy”	  
with	  Boolean	  phrase,	  AND,	  and	  	  “type	  2	  diabetes”	  was	  searched.	  	  This	  search	  was	  limited	  to	  
peer-­‐reviewed	  articles,	  published	  dates	  between	  the	  years	  2008	  through	  2016,	  and	  adult	  age	  
group	  only.	  	  This	  search	  revealed	  92	  results,	  of	  which	  six	  were	  saved.	  
	   Lastly,	  the	  PubMed	  database	  was	  accessed.	  	  Search	  terms	  included	  were	  “insulin	  pump”	  
and	  “type	  2	  diabetes”	  with	  a	  limit	  placed	  on	  articles	  published	  in	  the	  last	  five	  years.	  	  This	  
yielded	  44	  articles,	  of	  which	  three	  were	  kept.	  	  In	  summary,	  a	  total	  of	  16	  articles	  were	  obtained	  
for	  review.	  	  A	  summary	  of	  findings	  is	  discussed	  in	  the	  following	  sections.	  	  	  
Effectiveness	  of	  Continuous	  Subcutaneous	  Insulin	  Infusion	  (CSII)	  	  
	   In	  order	  to	  determine	  the	  effectiveness	  of	  an	  insulin	  or	  medication	  regimen	  and	  judge	  
how	  controlled	  blood	  glucose	  remains	  for	  a	  diabetic	  patient,	  glycated	  hemoglobin	  (hemoglobin	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A1c)	  is	  monitored.	  	  A	  value	  of	  <7%	  to	  <8%	  is	  preferred	  and	  individualized	  for	  each	  patient.	  	  An	  
objective	  of	  Healthy	  People	  2020	  is	  to	  reduce	  the	  proportion	  of	  persons	  with	  diabetes	  with	  a	  
hemoglobin	  A1c	  value	  greater	  than	  9.0%	  from	  17.9	  percent	  of	  adults	  to	  16.1	  percent	  of	  adults	  
(Office	  of	  Disease	  Prevention	  and	  Health	  Promotion,	  2014).	  	  Effectiveness	  of	  insulin	  therapy	  can	  
thereby	  be	  determined	  by	  monitoring	  A1c	  levels	  and	  obtaining	  a	  reduction	  in	  percentage	  from	  
previous	  readings,	  aiming	  for	  a	  goal	  of	  <8%.	  	  	  
	   A	  pilot	  study	  published	  by	  Wolff-­‐McDonagh	  et	  al.	  (2010),	  found	  significant	  reduction	  of	  
A1c	  with	  an	  average	  of	  9.4%	  at	  initiation	  to	  8.2%	  after	  one	  year	  of	  insulin	  pump	  therapy.	  	  
Following	  this	  study,	  a	  separately	  published	  analysis	  noted	  that	  after	  a	  16-­‐week	  course	  of	  
insulin	  pump	  therapy	  in	  sub-­‐optimally	  controlled	  type	  2	  diabetic	  patients,	  A1c	  decreased	  from	  
an	  average	  of	  8.4%	  to	  less	  than	  7%	  in	  90	  percent	  of	  the	  patients	  (Frias	  et	  al.,	  2011).	  	  Similarly,	  an	  
analysis	  of	  continuous	  data	  over	  three	  years	  of	  insulin	  pump	  therapy	  in	  the	  type	  2	  diabetic	  
patient	  shows	  an	  overall	  reduction	  of	  A1c	  from	  an	  average	  of	  9.66%	  to	  8.71%	  (Jankovec	  et	  al.,	  
2010).	  	  Although	  these	  results	  are	  promising,	  the	  reproducibility	  of	  the	  results	  suggest	  
otherwise	  due	  to	  the	  limited	  sample	  sizes	  of	  15,	  21,	  and	  54	  patients	  respectively.	  	  	  
Generally	  speaking,	  the	  research	  for	  use	  of	  insulin	  pump	  therapy	  in	  this	  population	  of	  
patients	  is	  lacking	  and	  outdated.	  	  The	  first	  RCT,	  which	  was	  comprised	  of	  127	  patients,	  
comparing	  MDI	  to	  CSII	  was	  published	  in	  2003	  and	  found	  that	  glycemic	  control	  was	  improved	  by	  
switching	  a	  patient	  from	  limited	  insulin	  therapy	  to	  intensive	  insulin	  therapy	  either	  by	  MDI	  or	  
CSII	  (Raskin	  et	  al.,	  2003).	  	  The	  CSII	  group	  in	  the	  Raskin	  et	  al.	  study	  had	  a	  more	  significant	  
reduction	  in	  A1c	  than	  the	  MDI	  group,	  and	  also	  reported	  satisfaction	  in	  the	  use	  of	  CSII	  due	  to	  
convenience	  and	  ease	  of	  use.	  	  In	  2005,	  another	  randomized	  controlled	  trial	  (RCT)	  was	  published	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to	  determine	  effectiveness	  of	  insulin	  pump	  therapy	  in	  the	  obese,	  uncontrolled	  type	  2	  diabetic	  
patient.	  	  This	  trial	  was	  composed	  of	  40	  patients,	  which	  were	  equally	  distributed	  to	  the	  insulin	  
pump	  therapy	  group	  or	  multiple	  daily	  injection	  (MDI)	  group.	  	  Results	  again	  determined	  that	  
insulin	  pump	  therapy	  was	  superior	  to	  MDI	  in	  decreasing	  A1c	  levels	  (Wainstein	  et	  al.,	  2005).	  	  	  
More	  recently,	  a	  larger	  scale	  RCT	  labeled,	  OpT2mise,	  was	  published	  in	  2014.	  	  This	  RCT	  
started	  by	  optimizing	  MDI	  therapy	  on	  the	  entire	  group,	  then	  randomly	  assigning	  and	  comparing	  
a	  group	  of	  163	  patients	  optimized	  on	  MDI	  versus	  a	  group	  of	  168	  patients	  with	  insulin	  pump	  
therapy.	  At	  initiation,	  average	  A1c	  was	  9.0%	  and	  decreased	  to	  7.9%	  in	  the	  insulin	  pump	  group	  
and	  to	  8.6%	  in	  the	  MDI	  group	  after	  six	  months	  (Reznik	  et	  al.,	  2014).	  	  Not	  only	  did	  this	  study	  
determine	  that	  insulin	  pump	  therapy	  can	  be	  effective	  in	  type	  2	  diabetes,	  but	  it	  also	  identified	  
appropriate	  candidates	  for	  this	  type	  of	  therapy	  because	  despite	  intensification	  and	  optimization	  
of	  MDI,	  their	  A1c	  levels	  did	  not	  show	  much	  improvement	  until	  placed	  on	  insulin	  pump	  therapy.	  	  
Comparing	  the	  findings	  listed	  above,	  insulin	  pump	  therapy	  does	  appear	  to	  be	  an	  
effective	  option	  in	  treating	  the	  patient	  with	  uncontrolled	  type	  2	  diabetes.	  	  Another	  finding	  of	  
interest	  in	  the	  OpT2mise	  trial	  and	  significant	  to	  the	  next	  topic	  of	  safety	  is	  that,	  “in	  the	  overall	  
patient	  population,	  the	  decrease	  in	  glycated	  hemoglobin	  was	  independent	  of	  diabetes	  duration,	  
body-­‐mass	  index,	  education	  level,	  Montreal	  Cognitive	  Assessment	  score,	  and	  number	  of	  blood-­‐
glucose	  self	  assessments	  done	  per	  day”	  (Reznik	  et	  al.,	  2014,	  pg.	  1268).	  	  	  
Safety	  Issues	  with	  CSII	  
	   Insulin	  use,	  whether	  by	  MDI	  or	  by	  CSII,	  involves	  certain	  risks.	  	  Insulin	  is	  a	  medication	  
designed	  to	  lower	  blood	  glucose.	  	  For	  a	  number	  of	  reasons,	  insulin	  injection	  or	  infusion	  can	  
cause	  blood	  glucose	  to	  become	  dangerously	  low.	  	  With	  a	  continuous	  infusion	  of	  insulin,	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hypoglycemia	  is	  a	  possibility	  and	  can	  become	  severe	  quickly	  if	  not	  addressed.	  	  Fortunately,	  
Resnik	  et	  al.	  (2014),	  Wainstein	  et	  al.	  (2005),	  Jankovec	  et	  al.	  (2009),	  and	  Frias	  et	  al.	  (2011),	  
conclude	  that	  severe	  hypoglycemia	  is	  not	  significantly	  increased	  when	  using	  CSII	  for	  type	  2	  
diabetes.	  	  It	  was	  also	  found	  that	  the	  time	  spent	  in	  hyperglycemia	  was	  lessened	  due	  to	  the	  
continuous	  basal	  rate	  of	  insulin	  and	  proper	  bolus	  doses	  given	  at	  meal	  times	  (Resnik	  et	  al.,	  
2014).	  These	  findings	  are	  important	  because	  the	  reduction	  of	  time	  spent	  in	  hyperglycemia	  
contributes	  to	  the	  reduction	  of	  complications	  associated	  with	  diabetes	  mellitus.	  	  In	  addition,	  
the	  risk	  of	  hypoglycemic	  events	  is	  low	  for	  patients	  with	  type	  2	  diabetes	  which	  rationalizes	  that	  
this	  therapy	  is	  safe.	  	  The	  next	  safety	  concern	  entails	  operation	  of	  insulin	  pumps.	  	  	  	  	  	  	  	  
	   Ability	  to	  operate	  and	  troubleshoot	  the	  insulin	  pump	  has	  been	  considered	  a	  risk	  for	  
therapy.	  	  As	  stated	  previously,	  the	  OpT2mise	  trial	  found	  by	  chance	  that	  the	  decrease	  in	  A1c	  was	  
independent	  of	  Montreal	  Cognitive	  Assessment	  scores.	  	  “38%	  of	  patients	  in	  the	  pump	  therapy	  
group	  had	  mild	  cognitive	  impairment”	  (Reznik	  et	  al.,	  2014,	  pg.	  1270)	  and	  were	  still	  able	  to	  
efficiently	  use	  the	  insulin	  pump.	  	  Also,	  with	  the	  advancement	  in	  technology,	  newer	  pumps	  are	  
more	  reliable,	  and	  have	  alarms	  for	  empty	  cartridges,	  low	  batteries,	  and	  occlusion	  of	  tubing	  or	  
faulty	  electronics	  (Cummins	  et	  al.,	  2010).	  	  Therefore,	  with	  proper	  education	  on	  usage	  of	  insulin	  
pumps	  and	  the	  automated	  mechanisms	  in	  place	  for	  the	  insulin	  pump	  user,	  safe	  use	  of	  this	  
technology	  is	  possible.	  	  
Despite	  being	  able	  to	  effectively	  use	  the	  pump,	  Meade	  and	  Rushton	  (2013)	  
administered	  a	  pump	  assessment	  questionnaire	  to	  89	  patients	  and	  found	  common	  areas	  of	  
deficiency	  of	  pump	  use	  including,	  “expired	  or	  no	  basal	  insulin	  prescription	  or	  insulin	  syringes	  in	  
the	  event	  of	  pump	  failure	  or	  removal,	  no	  mupirocin	  prescription	  for	  suspected	  site	  infections,	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and	  lack	  of	  in-­‐date	  glucagon	  kits”.	  	  The	  results	  from	  this	  questionnaire	  demonstrate	  that	  
appropriate	  education	  and	  periodic	  assessment	  of	  pump	  users	  is	  a	  necessity	  in	  order	  to	  ensure	  
continued	  safety	  while	  using	  CSII	  due	  to	  the	  complications	  that	  may	  arise	  when	  depending	  on	  
technology	  for	  insulin	  administration.	  	  	  
Overall,	  CSII	  can	  be	  considered	  a	  safe	  therapy	  for	  patients	  with	  type	  2	  diabetes	  relative	  
to	  MDI	  being	  that	  episodes	  of	  hypoglycemia	  are	  insignificant	  and	  use	  of	  the	  insulin	  pump	  is	  safe	  
with	  appropriate	  education.	  	  Because	  the	  patient	  with	  insulin	  pump	  therapy	  requires	  a	  certain	  
amount	  of	  education	  and	  follow-­‐up,	  resource	  utilization	  will	  be	  discussed	  in	  the	  next	  section	  in	  
regards	  to	  cost-­‐efficiency.	  	  	  	  	  	  
Cost-­‐Efficiency	  of	  CSII	  
Currently,	  “Medicare	  and	  private	  insurance	  companies	  place	  multiple	  restrictions	  on	  
coverage	  for	  insulin	  pump	  therapy	  in	  type	  2	  diabetes,	  thereby	  effectively	  denying	  access	  to	  this	  
treatment	  tool”	  (Wolff	  et	  al.,	  2010,	  pg.	  658).	  	  Although	  previous	  trials	  have	  demonstrated	  that	  
insulin	  pump	  therapy	  is	  effective	  in	  reducing	  A1c	  levels,	  cost-­‐effectiveness	  of	  this	  therapy	  must	  
also	  be	  acceptable	  for	  policy	  change	  to	  occur.	  	  Direct	  costs	  for	  diabetes	  include	  medical	  goods	  
and	  services	  and	  totaled	  $176	  billion	  in	  2012;	  Indirect	  costs	  are	  accrued	  from	  lost	  workdays,	  
restricted	  activity,	  disability,	  and	  early	  death	  and	  totaled	  $69	  billion	  in	  2012	  (Centers	  for	  
Disease	  Control	  and	  Prevention,	  2015).	  	  In	  order	  to	  determine	  if	  CSII	  would	  be	  cost	  efficient	  for	  
the	  patient	  with	  type	  2	  diabetes,	  the	  cost	  of	  MDI	  and	  the	  cost	  of	  long-­‐term	  complications	  of	  
uncontrolled	  type	  2	  diabetes	  need	  to	  be	  compared.	  	  	  	  	  
There	  is	  insufficient	  research	  regarding	  whether	  CSII	  therapy	  is	  more	  cost-­‐efficient	  than	  
MDI.	  	  Wolff	  et	  al.	  (2010)	  compared	  the	  cost	  of	  MDI	  versus	  CSII	  based	  upon	  the	  amount	  of	  daily	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insulin	  usage.	  	  The	  study	  found	  that	  patients	  requiring	  a	  basal	  amount	  of	  insulin	  of	  150	  units	  or	  
more	  per	  day	  had	  the	  benefit	  of	  a	  cost	  savings	  of	  approximately	  $12,000	  over	  four	  years	  if	  using	  
CSII,	  while	  using	  any	  less	  than	  150	  units	  per	  day	  did	  not	  prove	  to	  be	  cost-­‐effective.	  	  The	  small	  
sample	  size	  of	  15	  patients	  in	  this	  study	  makes	  it	  difficult	  to	  generalize	  these	  cost	  savings.	  
Regardless	  of	  the	  small	  sample	  size,	  the	  projections	  of	  cost	  for	  each	  category	  of	  basal	  insulin	  
usage	  is	  significant	  enough	  to	  gain	  attention	  and	  potential	  follow-­‐up	  research.	  	  	  
A	  meta-­‐analysis	  published	  in	  2010	  states	  that	  CSII	  is	  only	  cost-­‐effective	  when	  there	  are	  
moderate	  gains	  in	  reduction	  of	  A1c	  (at	  least	  0.9%	  decrease	  from	  an	  8.8%	  baseline)	  or	  when	  the	  
use	  of	  CSII	  versus	  MDI	  reduces	  episodes	  of	  hypoglycemia	  by	  50%	  (Cummins	  et	  al.,	  2010).	  	  This	  
meta-­‐analysis	  does	  carry	  a	  benefit	  in	  that	  it	  considers	  the	  cost	  savings	  from	  reduced	  
complications	  and	  treatment	  of	  co-­‐morbidities	  as	  a	  result	  of	  better	  glycemic	  control,	  but	  the	  
information	  collected	  was	  between	  the	  years	  2002	  and	  2007	  with	  numerical	  values	  
representative	  of	  healthcare	  in	  the	  United	  Kingdom,	  not	  the	  United	  States.	  	  The	  pilot	  study	  by	  
Wolff	  et	  al.	  (2010)	  does	  not	  include	  figures	  regarding	  complications,	  and	  figures	  were	  based	  on	  
American	  currency	  and	  average	  costs	  of	  treatment	  in	  2010.	  	  In	  order	  to	  get	  a	  better	  picture	  of	  
cost	  savings,	  analysis	  on	  current	  health	  care	  costs	  for	  diabetes	  and	  its	  complications	  should	  be	  
developed.	  	  
An	  area	  that	  should	  also	  be	  considered	  when	  discussing	  costs	  of	  care	  for	  the	  diabetic	  
patient	  is	  healthcare	  resource	  utilization.	  	  In	  a	  large	  claims	  analysis	  published	  in	  2010,	  it	  was	  
found	  that	  “after	  CSII	  initiation	  in	  the	  type	  2	  diabetic,	  the	  number	  of	  anti-­‐diabetic	  drugs	  
decreased	  by	  46%,	  the	  rates	  of	  emergency	  department	  visits	  and	  inpatient	  admissions	  
significantly	  decreased,	  and	  the	  rate	  of	  ambulatory	  visits	  significantly	  increased”	  (Lynch	  et	  al.,	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2010).	  	  The	  increase	  in	  ambulatory	  visits	  is	  likely	  due	  to	  increased	  need	  for	  education	  on	  use	  of	  
CSII,	  and	  not	  from	  disease	  progression	  due	  to	  the	  decrease	  in	  hospitalizations	  in	  this	  group.	  	  
Costs	  for	  emergency	  and	  inpatient	  care	  are	  considerably	  higher	  than	  for	  outpatient	  visits,	  so	  
eliminating	  this	  resource	  utilization	  is	  a	  significant	  factor	  in	  healthcare	  expense.	  	  Again,	  
although	  these	  results	  are	  significant,	  this	  is	  the	  only	  large-­‐scale	  analysis	  that	  reviews	  cost	  of	  
insulin	  therapy	  versus	  diabetic	  complications.	  	  	  
Conclusion	  and	  Learning	  Points	  
Conclusions	  drawn	  from	  this	  literature	  review	  include	  that	  CSII	  therapy	  versus	  MDI	  for	  
the	  uncontrolled	  type	  2	  diabetic	  patient	  can	  be	  effectively	  and	  safely	  used	  in	  patients.	  	  
Continuous	  subcutaneous	  insulin	  infusion	  versus	  multiple	  daily	  injections	  of	  insulin	  proved	  to	  
reduce	  hemoglobin	  A1c,	  even	  after	  optimization	  of	  MDI	  therapy	  took	  place.	  	  CSII	  is	  safe	  both	  in	  
regards	  to	  an	  insignificant	  number	  of	  hypoglycemic	  episodes	  related	  to	  this	  occurrence	  in	  the	  
MDI	  treated	  populations,	  and	  due	  to	  the	  findings	  that	  insulin	  pumps	  are	  easy	  to	  use	  even	  for	  
individuals	  with	  mild	  cognitive	  impairment.	  	  When	  discussing	  safety	  of	  insulin	  pumps,	  education	  
of	  their	  use	  is	  key,	  but	  should	  be	  considered	  alongside	  the	  cost	  of	  therapy	  being	  that	  pump	  
education	  is	  an	  area	  of	  resource	  utilization.	  	  	  
The	  cost	  of	  CSII	  is	  a	  topic	  of	  concern.	  	  At	  this	  point,	  Medicare	  and	  private	  insurance	  
companies	  are	  not	  convinced	  that	  this	  therapy	  is	  beneficial	  for	  cost	  savings	  and	  thus	  will	  not	  
cover	  this	  service.	  	  The	  pilot	  study	  previously	  discussed,	  did	  determine	  a	  cost	  savings	  for	  the	  
patient	  with	  type	  2	  diabetes	  if	  they	  were	  currently	  using	  a	  large	  amount	  of	  insulin	  with	  MDI.	  	  
More	  research	  and	  policy	  initiatives	  would	  be	  of	  benefit	  to	  determine	  the	  actual	  cost	  of	  therapy	  
versus	  cost	  of	  complications	  due	  to	  poor	  glycemic	  control.	  	  In	  one	  analysis,	  there	  were	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significant	  reductions	  in	  emergency	  department	  visits	  and	  hospitalizations	  due	  to	  diabetes	  after	  
insulin	  pump	  initiation,	  but	  there	  was	  an	  increase	  in	  ambulatory	  visits	  which	  changes	  the	  
allocation	  of	  resource	  utilization	  for	  this	  group	  of	  patients.	  	  The	  cost-­‐efficiency	  of	  insulin	  pump	  
therapy	  versus	  MDI	  can	  therefore	  not	  be	  determined	  with	  this	  limited	  amount	  of	  information.	  	  	  	  	  
The	  patient	  previously	  discussed	  as	  part	  of	  the	  case	  report	  is	  a	  type	  1	  diabetic	  patient	  
who	  benefits	  from	  CSII	  versus	  MDI.	  	  His	  glycemic	  control	  is	  adequate	  at	  this	  time	  with	  an	  A1c	  of	  
7.0%	  and	  he	  has	  no	  diagnoses	  related	  to	  complications	  from	  his	  diabetes.	  	  While	  he	  did	  report	  
ease	  of	  use	  of	  his	  insulin	  pump,	  he	  did	  note	  that	  episodes	  of	  hypoglycemia	  in	  the	  last	  six	  weeks	  
were	  more	  frequent.	  	  This,	  however,	  is	  likely	  due	  to	  an	  increase	  in	  activity	  with	  physical	  therapy	  
following	  his	  left	  knee	  replacement	  surgery.	  	  Cost	  for	  this	  patient	  cannot	  be	  compared	  to	  the	  
cost	  for	  a	  patient	  with	  type	  2	  diabetes,	  because	  this	  patient	  has	  type	  1	  diabetes	  and	  his	  insulin	  
pump	  therapy	  cost	  is	  covered	  by	  his	  insurance	  carrier.	  	  	  
Knowing	  that	  this	  patient	  transitioned	  from	  an	  uncontrolled	  state	  of	  diabetes	  to	  
attaining	  glycemic	  control	  after	  insulin	  pump	  therapy	  initiation,	  shows	  the	  increased	  
effectiveness	  CSII	  therapy.	  	  Research	  for	  the	  use	  of	  CSII	  in	  the	  uncontrolled	  type	  2	  diabetic	  
patient	  is	  promising	  in	  regards	  to	  effectiveness	  and	  safety,	  yet	  limiting	  in	  the	  scope	  of	  cost-­‐
efficiency.	  	  The	  following	  learning	  points	  can	  be	  made	  from	  the	  findings	  of	  this	  case	  report	  and	  
literature	  review:	  	  	  	  	  	  	  
•   Continuous	  subcutaneous	  insulin	  infusion	  therapy	  (CSII),	  or	  insulin	  pump	  therapy,	  is	  an	  
effective	  tool	  in	  attaining	  glycemic	  control	  and	  limiting	  episodes	  of	  severe	  hypoglycemia	  
and	  hyperglycemia	  for	  type	  1	  diabetics	  and	  should	  be	  considered	  for	  patients	  with	  
uncontrolled	  type	  2	  diabetes.	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•   CSII	  is	  a	  safe	  therapy	  given	  proper	  education	  on	  use	  and	  maintenance	  of	  the	  insulin	  
pump	  and	  instructions	  on	  what	  do	  if	  the	  pump	  fails.	  	  	  
•   Although	  Medicare	  and	  private	  insurance	  companies	  are	  willing	  to	  defer	  the	  cost	  of	  
insulin	  pump	  therapy	  for	  type	  1	  diabetic	  patients,	  they	  have	  restrictions	  on	  cost	  
coverage	  for	  type	  2	  diabetes.	  	  Additional	  research	  is	  warranted	  that	  analyzes	  the	  cost	  
accrued	  from	  the	  many	  complications	  and	  co-­‐morbidities	  from	  type	  2	  diabetes	  to	  see	  if	  
this	  outweighs	  the	  annual	  cost	  for	  CSII.	  	  
•   Until	  proper	  cost	  analysis	  can	  be	  performed,	  the	  use	  of	  CSII	  in	  the	  uncontrolled	  type	  2	  
diabetic	  patient,	  while	  beneficial	  for	  a	  patient’s	  health,	  may	  be	  severely	  limited	  due	  to	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